186 related articles for article (PubMed ID: 36710594)
1. The role of cytoreductive nephrectomy in the immuno-oncological therapy era.
Magee DE; Helstrom E; Kutikov A
Curr Opin Urol; 2023 Mar; 33(2):136-141. PubMed ID: 36710594
[TBL] [Abstract][Full Text] [Related]
2. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?
Kokorovic A; Rendon RA
Curr Opin Support Palliat Care; 2019 Sep; 13(3):255-261. PubMed ID: 31082942
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
5. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
6. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Graham J; Bhindi B; Heng DYC
Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
[TBL] [Abstract][Full Text] [Related]
8. Role of cytoreductive nephrectomy in renal cell carcinoma.
Chiong E; Wood CG; Margulis V
Future Oncol; 2009 Aug; 5(6):859-69. PubMed ID: 19663735
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
11. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice.
Soares A; Maia MC; Vidigal F; Marques Monteiro FS
Oncology; 2020; 98(1):1-9. PubMed ID: 31514196
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything?
Grant M; Szabados B; Kuusk T; Powles T; Bex A
Curr Opin Urol; 2020 Jan; 30(1):36-40. PubMed ID: 31789991
[TBL] [Abstract][Full Text] [Related]
14. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy in the era of targeted therapies: a review.
Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
Biles MJ; Patel HD; Allaf ME
Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?
Dilme RV; Rivas JG; Campi R; Puente J; Jerez T; Enikeev D; Esperto F; Sierra JM
Curr Urol Rep; 2021 Oct; 22(11):54. PubMed ID: 34654989
[TBL] [Abstract][Full Text] [Related]
18. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
19. Role of cytoreductive surgery in the era of immunotherapy.
Isali I; Braun A; Bukavina L; Psutka SP
Curr Opin Urol; 2022 Nov; 32(6):618-626. PubMed ID: 36081404
[TBL] [Abstract][Full Text] [Related]
20. Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma.
Reese SW; Eismann L; White C; Villada JA; Khaleel S; Ostrovnaya I; Vazquez-Rivera K; Carlo MI; Feldman D; Lee CH; Motzer R; Voss MH; Kotecha RR; Matulewicz RS; Goh A; Coleman J; Russo P; Hakimi AA
Urol Oncol; 2024 Feb; 42(2):32.e9-32.e16. PubMed ID: 38135627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]